Literature DB >> 2496972

Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential.

W M Franz1, P Berger, J Y Wang.   

Abstract

The requirements for the oncogenic conversion of the c-abl proto-oncogene have been determined by the expression of N-terminal deleted forms and viral gag-fused forms of the c-abl proteins from a selectable retroviral vector. To activate the transforming potential of c-abl, it is necessary that (i) specific N-terminal amino acids are deleted to release the kinase from negative regulation in vivo; (ii) an N-terminal myristylation site is part of the activated kinase; (iii) the fatty-acylated, activated kinase is overproduced. The N-terminal amino acids found to be necessary for the cellular inhibition of c-abl tyrosine phosphorylation are part of a homologous region present in many non-receptor tyrosine kinases, the v-crk oncogene and phospholipase C-II. Overproduction of a deregulated and myristylated c-abl tyrosine kinase induces the transformation of NIH 3T3 cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496972      PMCID: PMC400782          DOI: 10.1002/j.1460-2075.1989.tb03358.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  47 in total

1.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

2.  The mouse c-abl locus: molecular cloning and characterization.

Authors:  J Y Wang; F Ledley; S Goff; R Lee; Y Groner; D Baltimore
Journal:  Cell       Date:  1984-02       Impact factor: 41.582

3.  Cloning and analysis of reverse transcript P160 genomes of Abelson murine leukemia virus.

Authors:  S A Latt; S P Goff; C J Tabin; M Paskind; J Y Wang; D Baltimore
Journal:  J Virol       Date:  1983-03       Impact factor: 5.103

4.  Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA.

Authors:  S P Goff; E Gilboa; O N Witte; D Baltimore
Journal:  Cell       Date:  1980-12       Impact factor: 41.582

5.  Transfection of fibroblasts by cloned Abelson murine leukemia virus DNA and recovery of transmissible virus by recombination with helper virus.

Authors:  S P Goff; C J Tabin; J Y Wang; R Weinberg; D Baltimore
Journal:  J Virol       Date:  1982-01       Impact factor: 5.103

6.  Sequences of the A-MuLV protein needed for fibroblast and lymphoid cell transformation.

Authors:  R Prywes; J G Foulkes; N Rosenberg; D Baltimore
Journal:  Cell       Date:  1983-09       Impact factor: 41.582

7.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia.

Authors:  A de Klein; A G van Kessel; G Grosveld; C R Bartram; A Hagemeijer; D Bootsma; N K Spurr; N Heisterkamp; J Groffen; J R Stephenson
Journal:  Nature       Date:  1982-12-23       Impact factor: 49.962

8.  Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia.

Authors:  N Heisterkamp; J R Stephenson; J Groffen; P F Hansen; A de Klein; C R Bartram; G Grosveld
Journal:  Nature       Date:  1983 Nov 17-23       Impact factor: 49.962

9.  The Hardy-Zuckerman 2-FeSV, a new feline retrovirus with oncogene homology to Abelson-MuLV.

Authors:  P Besmer; W D Hardy; E E Zuckerman; P Bergold; L Lederman; H W Snyder
Journal:  Nature       Date:  1983-06-30       Impact factor: 49.962

10.  Cellular RNA homologous to the Abelson murine leukemia virus transforming gene: expression and relationship to the viral sequence.

Authors:  J Y Wang; D Baltimore
Journal:  Mol Cell Biol       Date:  1983-05       Impact factor: 4.272

View more
  60 in total

1.  Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization.

Authors:  Y Nie; H H Li; C M Bula; X Liu
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

2.  Two distinct phosphorylation pathways have additive effects on Abl family kinase activation.

Authors:  Keith Q Tanis; Darren Veach; Henry S Duewel; William G Bornmann; Anthony J Koleske
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

3.  Biological and biochemical activity of v-Crk chimeras containing the SH2/SH3 regions of phosphatidylinositol-specific phospholipase C-gamma and Src.

Authors:  M Matsuda; C T Reichman; H Hanafusa
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Human bcr-abl gene has a lethal effect on embryogenesis.

Authors:  N Heisterkamp; G Jenster; D Kioussis; P K Pattengale; J Groffen
Journal:  Transgenic Res       Date:  1991-12       Impact factor: 2.788

5.  Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.

Authors:  J R McWhirter; J Y Wang
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

6.  Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein.

Authors:  Chae-Ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

7.  En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.

Authors:  A J Muller; A M Pendergast; K Parmar; M H Havlik; N Rosenberg; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

8.  Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line.

Authors:  G Q Daley; R A Van Etten; P K Jackson; A Bernards; D Baltimore
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

9.  A 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells.

Authors:  E Freed; T Hunter
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

10.  Both the SH2 and SH3 domains of human CRK protein are required for neuronal differentiation of PC12 cells.

Authors:  S Tanaka; S Hattori; T Kurata; K Nagashima; Y Fukui; S Nakamura; M Matsuda
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.